[HTML][HTML] Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19
…, P Lenehan, A Puranik, MT Seville, LL Speicher… - …, 2021 - thelancet.com
Background Real-world clinical data to support the use of casirivimab–imdevimab for the
treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is needed. …
treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is needed. …
Real-world clinical outcomes of bamlanivimab and casirivimab-imdevimab among high-risk patients with mild to moderate coronavirus disease 2019
…, JK Rosedahl, MT Seville, LL Speicher… - The Journal of …, 2021 - academic.oup.com
Background Bamlanivimab and casirivimab-imdevimab are authorized for treatment of mild
to moderate coronavirus disease 2019 (COVID-19) in high-risk patients. We compared the …
to moderate coronavirus disease 2019 (COVID-19) in high-risk patients. We compared the …
[HTML][HTML] COVID-19 infection in solid organ transplant recipients after SARS-CoV-2 vaccination
…, JC Leoni, SZ Shah, N Aslam, LL Speicher - American journal of …, 2021 - ncbi.nlm.nih.gov
The prevalence and mortality of COVID-19 are higher in solid organ transplant recipients (SOTs)
compared to the general population. 1-3 Two SARS-CoV-2 messenger RNA (mRNA) …
compared to the general population. 1-3 Two SARS-CoV-2 messenger RNA (mRNA) …
[HTML][HTML] Implementation of a multisite, interdisciplinary remote patient monitoring program for ambulatory management of patients with COVID-19
…, A Virk, R Orenstein, LL Speicher… - npj Digital …, 2021 - nature.com
Established technology, operational infrastructure, and nursing resources were leveraged
to develop a remote patient monitoring (RPM) program for ambulatory management of …
to develop a remote patient monitoring (RPM) program for ambulatory management of …
[HTML][HTML] Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19
…, R Orenstein, A Puranik, LL Speicher… - The Journal of …, 2021 - Am Soc Clin Investig
BACKGROUND Clinical data to support the use of bamlanivimab for the treatment of
outpatients with mild to moderate coronavirus disease-19 (COVID-19) are needed. METHODS …
outpatients with mild to moderate coronavirus disease-19 (COVID-19) are needed. METHODS …
A framework for outpatient infusion of antispike monoclonal antibodies to high-risk patients with mild-to-moderate coronavirus disease-19: the Mayo Clinic model
…, MT Seville, EC Skold, JM Smith, LL Speicher… - Mayo Clinic …, 2021 - Elsevier
The administration of spike monoclonal antibody treatment to patients with mild to moderate
COVID-19 is very challenging. This article summarizes essential components and …
COVID-19 is very challenging. This article summarizes essential components and …
Comparable outcomes for bebtelovimab and ritonavir-boosted nirmatrelvir treatment in high-risk patients with coronavirus disease-2019 during severe acute …
…, SN Hanson, RF Arndt, LL Speicher… - The Journal of …, 2022 - academic.oup.com
The effectiveness of bebtelovimab in real-world settings has not been assessed. In this
retrospective cohort study of 3607 high-risk patients, bebtelovimab was used more commonly …
retrospective cohort study of 3607 high-risk patients, bebtelovimab was used more commonly …
Surveillance of safety of 3 doses of COVID-19 mRNA vaccination using electronic health records
…, PJ Lenehan, A Virk, MD Swift, LL Speicher… - JAMA network …, 2022 - jamanetwork.com
Importance Recent reports on waning of COVID-19 vaccine–induced immunity have led to
the approval and rollout of additional doses and booster vaccinations. Individuals at …
the approval and rollout of additional doses and booster vaccinations. Individuals at …
COVID-19 drive through testing: an effective strategy for conserving personal protective equipment
AN Ton, T Jethwa, K Waters, LL Speicher… - American journal of …, 2020 - ajicjournal.org
1. Li Q. An outbreak of NCIP (2019-nCoV) infection in China—Wuhan, Hubei Province, 2019−
2020. China CDC Wkly. 2020; 2: 79–80. 2. Tang B, Bragazzi NL, Li Q, Tang S, Xiao Y, Wu …
2020. China CDC Wkly. 2020; 2: 79–80. 2. Tang B, Bragazzi NL, Li Q, Tang S, Xiao Y, Wu …
[HTML][HTML] Outcomes of COVID-19 with the Mayo Clinic model of care and research
Objective To report the Mayo Clinic experience with coronavirus disease 2019 (COVID-19)
related to patient outcomes. Methods We conducted a retrospective chart review of patients …
related to patient outcomes. Methods We conducted a retrospective chart review of patients …